Zobrazeno 1 - 10
of 7 006
pro vyhledávání: '"cancer management"'
Publikováno v:
Cancer Medicine, Vol 13, Iss 18, Pp n/a-n/a (2024)
Abstract Background Early studies indicated that corticosteroids may limit the survival benefit from immunotherapy. We conducted this systematic review to evaluate the effect corticosteroids have on immunotherapy in patients with malignancy, when adj
Externí odkaz:
https://doaj.org/article/9f3f1ec0c82246868a29b1500c329c31
Autor:
Deloris J. Veney, Lai Y. Wei, Amanda E. Toland, Carolyn J. Presley, Heather L. Hampel, Tasleem J. Padamsee, Clara N. Lee, William J. Irvin Jr, Michael J. Bishop, James J. Kim, Shelly R. Hovick, Leigha A. Senter, Daniel G. Stover
Publikováno v:
Cancer Medicine, Vol 13, Iss 17, Pp n/a-n/a (2024)
Abstract Introduction Tumor genomic testing (TGT) is standard‐of‐care for most patients with advanced/metastatic cancer. Despite established guidelines, patient education prior to TGT is frequently omitted. The purpose of this study was to evalua
Externí odkaz:
https://doaj.org/article/0f51ff3d583d483a9f9096298c4b2656
Publikováno v:
Genes and Diseases, Vol 11, Iss 2, Pp 807-818 (2024)
Immune checkpoint inhibitors (ICIs) are monoclonal antibody antagonists, which can block cytotoxic T lymphocyte antigen-4 (CTLA-4), programmed death-1/ligand-1 (PD-1/PD-L1) pathways, and other molecules exploited by tumor cells to evade T cell-mediat
Externí odkaz:
https://doaj.org/article/ffeb053e24d440bfa4a1a3d9d78c654a
Autor:
Yuko Shirouchi, Kazumi Kaihara, Tsunaki Sekita, Naoko Amano, Konosuke Nakayama, Kazunori Miyake, Hitoshi Abe, Hirotoshi Oinuma, Dai Maruyama
Publikováno v:
Cancer Medicine, Vol 13, Iss 16, Pp n/a-n/a (2024)
Abstract Background Immunofixation electrophoresis (IFE) is the standard method for confirming the presence of a monoclonal protein (M‐protein) at multiple myeloma (MM) diagnosis. IFE is also essential at assessment of complete response (CR) and st
Externí odkaz:
https://doaj.org/article/fe7b00a305a04d63ae57a9652c70c1c5
Autor:
Binafsha Manzoor Syed
Publikováno v:
Liaquat Medical Research Journal, Vol 6, Iss 2 (2024)
Cancer survivorship has improved in the recent years due to screening facilities, modernized treatment options and advanced cancer care in specialized centers globally. However, in low-middle-income countries cancer survivorship is not yet improved t
Externí odkaz:
https://doaj.org/article/577519279a6b4e4cb24017d0cc089e54
Publikováno v:
Frontiers in Nutrition, Vol 11 (2024)
Human studies have shown the anticancer effects of dietary isothiocyanates (ITCs), but there are some inconsistencies, and more evidence supports that such anticancer effect is from higher doses of ITCs. The inconsistencies found in epidemiological s
Externí odkaz:
https://doaj.org/article/5bc267f161d74d60af98fc73499be219
Autor:
Janice P. Richmond, Mary Grace Kelly, Alison Johnston, Patrick J. Murphy, Laura O’Connor, Paddy Gillespie, Anna Hobbins, Alberto Alvarez-Iglesias, Andrew W. Murphy
Publikováno v:
Pilot and Feasibility Studies, Vol 10, Iss 1, Pp 1-15 (2024)
Abstract Oral anti-cancer medications (OAMs) are being used increasingly within cancer care. OAMs offer the potential to improve patient convenience and increase hospital capacity. The clinical assessment for each cycle of OAMs requires specialist pa
Externí odkaz:
https://doaj.org/article/771a3e1e4bea4277926e917e6931de99
Autor:
Shogo Wada, Tomone Watanabe, Taisuke Ishii, Yuichi Ichinose, Ryoko Rikitake, Dai Ogata, Eiji Nakano, Kenjiro Namikawa, Naoya Yamazaki, Takahiro Higashi
Publikováno v:
Cancer Medicine, Vol 12, Iss 23, Pp 21364-21372 (2023)
Abstract Background Sentinel lymph node biopsy (SLNB) underuse has been reported for skin cancers; however, actual performance rates have not been compared. The objective of this study was to investigate the SLNB performance rate in skin cancers cove
Externí odkaz:
https://doaj.org/article/4ab7b682bb6047b8b163da6bd0361dca
Autor:
Lorenzo Pradelli, Massimo Massaia, Elisabetta Todisco, Filippo Gherlinzoni, Anna Furlan, Maria La Targia, Elisabetta Grande, Ignazio Ezio Tripoli, Francesca Occhipinti, Francesco Comello, Fabrizio Iannello, Stefania Bellucci
Publikováno v:
Cancer Medicine, Vol 12, Iss 23, Pp 21480-21489 (2023)
AbstractBackgroundDaratumumab is a humanized monoclonal antibody approved for the treatment of adult patients with newly diagnosed or relapsed/refractory multiple myeloma (RRMM). Subcutaneous (SC) formulation proved to be non‐inferior in comparison
Externí odkaz:
https://doaj.org/article/5dcf619164e4483fa8e61f35f99b0399